<DOC>
	<DOCNO>NCT01276639</DOCNO>
	<brief_summary>The main objective study compare effect CP-690,550 effect placebo patient treat moderate severe chronic plaque psoriasis . This one-year study also evaluate safety tolerability CP-690,550 versus placebo .</brief_summary>
	<brief_title>A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Are 18 year old diagnosis least 12 month moderate severe plaque psoriasis cover least 10 % body surface area Psoriasis Area Severity Index ( PASI ) score 12 consider candidate systemic light therapy No evidence active latent tuberculosis Nonplaque drug induce form psoriasis discontinue current oral , injectible topical therapy psoriasis discontinue phototherapy ( PUVA UVB ) uncontrolled significant medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Xeljanz</keyword>
	<keyword>tofacitinib</keyword>
	<keyword>chronic</keyword>
	<keyword>Pruritus</keyword>
	<keyword>Itch</keyword>
	<keyword>DLQI</keyword>
	<keyword>severe</keyword>
	<keyword>moderate</keyword>
	<keyword>treatment</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>CP-690,550</keyword>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>Psoriasis Vulgaris</keyword>
	<keyword>Jax-inhibitor</keyword>
	<keyword>Oral Treatment</keyword>
</DOC>